What is Zacks Research’s Forecast for BDX Q2 Earnings?

Becton, Dickinson and Company (NYSE:BDX) – Stock analysts at Zacks Research cut their Q2 2025 earnings estimates for Becton, Dickinson and Company in a research note issued to investors on Wednesday, February 26th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will post earnings of $3.28 per share for the quarter, down from their prior estimate of $3.45. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.43 per share. Zacks Research also issued estimates for Becton, Dickinson and Company’s Q3 2025 earnings at $3.58 EPS, Q4 2025 earnings at $4.14 EPS, Q1 2026 earnings at $3.21 EPS, Q2 2026 earnings at $3.79 EPS, Q3 2026 earnings at $4.06 EPS and Q1 2027 earnings at $3.46 EPS.

BDX has been the topic of several other research reports. Barclays upped their price target on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Piper Sandler upped their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. Finally, StockNews.com downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Tuesday. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Moderate Buy” and an average target price of $278.29.

Becton, Dickinson and Company Stock Up 0.6 %

Shares of NYSE BDX opened at $225.57 on Friday. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $251.99. The company has a market capitalization of $64.77 billion, a PE ratio of 37.47, a price-to-earnings-growth ratio of 1.63 and a beta of 0.40. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63. The firm’s 50-day moving average is $233.08 and its two-hundred day moving average is $233.05.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%.

Institutional Trading of Becton, Dickinson and Company

Institutional investors and hedge funds have recently bought and sold shares of the business. Brighton Jones LLC increased its position in Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares in the last quarter. E. Ohman J or Asset Management AB increased its position in Becton, Dickinson and Company by 13.4% during the 4th quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier’s stock worth $39,951,000 after purchasing an additional 20,859 shares in the last quarter. Arete Wealth Advisors LLC acquired a new stake in Becton, Dickinson and Company during the 3rd quarter worth approximately $767,000. Busey Bank increased its position in Becton, Dickinson and Company by 3.8% during the 4th quarter. Busey Bank now owns 66,255 shares of the medical instruments supplier’s stock worth $15,031,000 after purchasing an additional 2,399 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Becton, Dickinson and Company by 79.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after purchasing an additional 1,317,723 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In other news, Director Jeffrey William Henderson purchased 1,500 shares of the company’s stock in a transaction on Monday, February 10th. The stock was bought at an average cost of $233.62 per share, for a total transaction of $350,430.00. Following the completion of the purchase, the director now directly owns 8,015 shares of the company’s stock, valued at $1,872,464.30. The trade was a 23.02 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bertram L. Scott sold 700 shares of the firm’s stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total value of $159,593.00. Following the completion of the transaction, the director now owns 36,033 shares in the company, valued at approximately $8,215,163.67. This trade represents a 1.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,544 shares of company stock valued at $2,370,309. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company announced that its Board of Directors has initiated a stock buyback plan on Tuesday, January 28th that permits the company to repurchase 10,000,000 shares. This repurchase authorization permits the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be paid a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 1.84%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s payout ratio is 69.10%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.